Incyte Treats First Patient in Phase II GVHD Study on Jakafi

Incyte Corporation INCY announced that the first patient has been treated in the pivotal phase II REACH 1 study assessing its marketed drug Jakafi in combination with corticosteroids for the treatment of steroid refractory acute graft versus host disease GVHD Incyte s share price has